Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?

Author(s): Sultan Almuntashiri, Duo Zhang, Payaningal R. Somanath and Andrea Sikora*

Volume 23, Issue 1, 2023

Published on: 10 August, 2022

Article ID: e190622206159 Pages: 3

DOI: 10.2174/1871526522666220619121539

Abstract

Identifying novel therapies is a critical need in the treatment of coronavirus disease-19 (COVID-19) and acute respiratory distress syndrome (ARDS). Stromelysin-1, also known as matrixmetalloproteinase 3 (MMP3), has been investigated as a diagnostic biomarker and a potential pharmacological target. Here, we discuss the recent findings of Gelzo et al. in the context of additional MMP3 investigations to delineate its exact role in diagnosis, prognostication, and phenotyping, in addition to its promising role as a therapeutic target in COVID-19-associated respiratory failure.

Keywords: Biomarker, potential pharmacological target, therapeutic target, respiratory failure, MMP3, ARDS.

[1]
Gelzo M, Cacciapuoti S, Pinchera B, et al. Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients. Sci Rep 2022; 12: 1212.
[http://dx.doi.org/10.1038/s41598-021-04677-8]
[2]
Artham S, Verma A, Newsome AS, Somanath PR. Patients with acute respiratory distress syndrome exhibit increased stromelysin1 activity in the blood samples. Cytokine 2020; 131: 155086.
[http://dx.doi.org/10.1016/j.cyto.2020.155086] [PMID: 32272349]
[3]
Artham S, Gao F, Verma A, et al. Endothelial stromelysin1 regulation by the forkhead box-O transcription factors is crucial in the exudative phase of acute lung injury. Pharmacol Res 2019; 141: 249-63.
[http://dx.doi.org/10.1016/j.phrs.2019.01.006] [PMID: 30611853]
[4]
Characterisation WHOWGC. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20(8): e192-7.
[http://dx.doi.org/10.1016/S1473-3099(20)30483-7] [PMID: 32539990]
[5]
Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers 2019; 5(1): 18.
[http://dx.doi.org/10.1038/s41572-019-0069-0] [PMID: 30872586]
[6]
Kadry R, Newsome AS, Somanath PR. Pharmacological inhibition of MMP3 as a potential therapeutic option for COVID-19 associated acute respiratory distress syndrome. Infect Disord Drug Targets 2021; 21(6): e170721187996.
[http://dx.doi.org/10.2174/1871526520666201116100310] [PMID: 33200717]
[7]
Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014; 2(8): 611-20.
[http://dx.doi.org/10.1016/S2213-2600(14)70097-9] [PMID: 24853585]
[8]
Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: A prospective observational study. Lancet Respir Med 2020; 8(12): 1209-18.
[http://dx.doi.org/10.1016/S2213-2600(20)30366-0] [PMID: 32861275]
[9]
Kadry RW, Adil MS, Newsome AS, Somanath PR. Cisatracurium attenuates LPS-induced modulation of MMP3 and junctional protein expression in human microvascular endothelial cells. Biosci Trends 2021; 15(1): 50-4.
[http://dx.doi.org/10.5582/bst.2020.03399] [PMID: 33627570]
[10]
Hall JB. Point: Should paralytic agents be routinely used in severe ARDS? Yes Chest 2013; 144(5): 1440-2.
[http://dx.doi.org/10.1378/chest.13-1460] [PMID: 24189854]
[11]
Mohamed AA, Mohamed N, Mohamoud S, et al. SARS-CoV-2: The path of prevention and control. Infect Disord Drug Targets 2021; 21(3): 358-62.
[http://dx.doi.org/10.2174/1871526520666200520112848] [PMID: 32433010]
[12]
Abd-Elsalam S, Salama M, Soliman S, et al. Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. Am J Trop Med Hyg 2021; 106(3): 886-90.
[http://dx.doi.org/10.4269/ajtmh.21-0606] [PMID: 34649223]
[13]
El-Bendary M, Abd-Elsalam S, Elbaz T, et al. AbdAllah, M.; Essam, M.; El-Shazly, M.; Esmat, G. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: A multicenter Egyptian study. Expert Rev Anti Infect Ther 2022; 20(2): 291-5.
[http://dx.doi.org/10.1080/14787210.2021.1950532] [PMID: 34225541]
[14]
Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. J Med Virol 2021; 93(10): 5833-8.
[http://dx.doi.org/10.1002/jmv.27122] [PMID: 34076901]

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy